Janney Montgomery Scott Initiates Coverage on NPS Pharmaceuticals (NPSP)
Equities research analysts at Janney Montgomery Scott began coverage on shares of NPS Pharmaceuticals (NASDAQ:NPSP) in a research note issued to investors on Thursday. The firm set a “buy” rating on the stock.
A number of other analysts have also recently weighed in on NPSP. Analysts at Zacks reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Tuesday, May 13th. They now have a $33.00 price target on the stock. Separately, analysts at Leerink Swann reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Friday, May 9th. They now have a $40.00 price target on the stock, down previously from $47.00. Finally, analysts at Needham & Company LLC cut their price target on shares of NPS Pharmaceuticals from $46.00 to $40.00 in a research note on Friday, May 9th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.93.
NPS Pharmaceuticals (NASDAQ:NPSP) traded up 1.65% on Thursday, hitting $26.46. 282,988 shares of the company’s stock traded hands. NPS Pharmaceuticals has a one year low of $14.06 and a one year high of $39.68. The stock has a 50-day moving average of $26.25 and a 200-day moving average of $29.79. The company’s market cap is $2.813 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.02) by $0.04. The company had revenue of $44.04 million for the quarter, compared to the consensus estimate of $48.30 million. During the same quarter last year, the company posted ($0.09) earnings per share. NPS Pharmaceuticals’s revenue was up 73.2% compared to the same quarter last year. On average, analysts predict that NPS Pharmaceuticals will post $0.02 earnings per share for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.